Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
Magrolimab for Solid Tumors Clinical Trial 2023 | Power
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML | Leukemia and Lymphoma Society
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
FORTY SEVEN, INC.
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma - ScienceDirect
EHA Library - The official digital education library of European Hematology Association (EHA)
Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
Effect of CD47 Blockade on Vascular Inflammation | NEJM
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | Business Wire
Corporate Overview
Cells | Free Full-Text | Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Magrolimab Achieving Positive Results in Phase 1b Trial of Untreated AML
CD47-SIRPα Drug Target Minireview - Drug Hunter
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Magrolimab + Aza for AML - Slideset Download - Clinical Oncology 2022 | CCO
Magrolimab - Multiple Myeloma Clinical Trials
New directions for emerging therapies in acute myeloid leukemia: the next chapter | Blood Cancer Journal
